Generic version of Pfizer's CDK4,6 inhibitor launched January 11, 2023 - "Sun Pharmaceutical Industries has launched the generic version of Pfizer's breast cancer medicine palbociclib (CDK4,6 inhibitor-Ibrance) in India on January 11. The entry of the generic medicine became possible after Pfizer's Indian patent on the product expired this month. The generic versions of the drug are also being readied by a handful of other Indian companies like Cipla and Dr Reddy's, and the price of the medicine is likely to come down significantly in the coming days, industry experts said."
https://www.fortuneindia.com/enterprise/sun-pharma-launches-generic-version-of-pfizers-blockbuster-cancer-drug/111110
This is the beginning of a series of patent losses that Big Pharma is set to face.
In contrast, ONCY's pelareorep is an innovative and novel "Phase 3 ready" biologic that can potentially acheve an accelerated approval and work to off-set several Big Pharma patent losses when combined with some of those soon to be off-patent drugs such as Pfizer's CDK4,6 inhibitor Ibrance. Furthermore, as a biologic ONCY's pelareorep is eligible for the FDA's 13 years of market exclusivity from the day of the marketing approval is granted.